VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company"),is pleased to announce the appointment of Mr. Jared Rushton to its Board of Directors, effective immediately. Mr. Rushton brings over a decade of experience in the public markets, with a strong background in corporate development, strategic advisory, and capital markets planning. Throughout his career, he has worked closely with emerging and growth-stage companies to support financing initiatives, investor engagement, market positioning, and operational execution.

His diverse industry experience spans the mining, cannabis, and biotech and health sciences sectors, where he has played a key role in evaluating strategic opportunities, structuring partnerships, and guiding long-term growth strategies. Mr. Rushton has also advised on go-public transactions, corporate restructuring, and business development programs designed to enhance corporate value and strengthen shareholder alignment.

Mr. Rushton replaces Mr. Zachary Stadnyk, who has stepped down from the Board. The Company extends its gratitude to Mr. Stadnyk for his dedication and contributions during his tenure.

The Company also announces the engagement of MCS Market Communication Service GmbH (business address: Saarlandstraße 28 58511 Lüdenscheid, Germany, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the "Services"). The Services are expected to run until December 15, 2025 or budget exhaustion. The Company has paid MCS EUR 600,000 as consideration for its services. No securities have been provided to MCS or its principals as compensation for the Services. The Services will be executed via digital channels, including Google Ads and native advertising.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited